The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
[18F]Fluorodeoxyglucose Uptake by Positron Emission Tomography Predicts Outcome of Non–Small-Cell Lung Cancer
Abstract
Purpose: To determine whether the standardized uptake value (SUV) of [18 F]fluorodeoxyglucose uptake by positron emission tomography could be a prognostic factor for non–small-cell lung cancer (NSCLC). Patients and Methods: One hundred sixty-two patients with stage I to IIIb NSCLC were analyzed. Overall survival (OS), disease-free survival (DFS), distant metastasis-free survival (DMFS), and local-regional control (LRC) were calculated by the Kaplan-Meier method and evaluated with the log-rank test. The prognostic significance was assessed by univariate and multivariate analyses. Results: There were 93 patients treated with surgery and 69 patients treated with radiotherapy. A cutoff of 5 for the SUV for the primary tumor showed the best discriminative value. The SUV for the primary tumor was a significant predictor of OS (P = .02) in both groups. Low SUVs (≤ 5.0) showed significantly better DFS rates than those with high SUVs (> 5.0; surgery group, P = .02; radiotherapy group, P = .0005). Low SUVs (≤ 5.0) indicated a significantly better DFS than those with high SUVs (> 5.0; stage I or II, P = .02; stage IIIa or IIIb, P = .004). However, using the same cutoff point of 5, the SUV for regional lymph nodes was not a significant indicator for DFS (P = .19), LRC (P = .97), or DMFS (P = .17). The multivariate analysis showed that the SUV for the primary tumor was a significant prognostic factor for OS (P = .03) and DFS (P = .001). Conclusion: The SUV of the primary tumor was the strongest prognostic factor among the patients treated by curative surgery or radiotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. J. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.1.5 · Cited by 3,275
Bos, R., van der Hoeven, J. J. M., van der Wall, E., van der Groep, P., van Diest, P. J., Comans, E. F. I., Joshi, U., Semenza, G. L., Hoekstra, O. S., Lammertsma, A. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.2.379 · Cited by 591
Vansteenkiste, J. F., Stroobants, S. G., Dupont, P. J., De Leyn, P. R., Verbeken, E. K., Deneffe, G. J., Mortelmans, L. A., & Demedts, M. G. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3201 · Cited by 439
Mac Manus, M. P., Hicks, R. J., Matthews, J. P., McKenzie, A., Rischin, D., Salminen, E. K., & Ball, D. L. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.054 · Cited by 439
Vansteenkiste, J. F., Stroobants, S. G., De Leyn, P. R., Dupont, P. J., Bogaert, J., Maes, A., Deneffe, G. J., Nackaerts, K. L., Verschakelen, J. A., Lerut, T. E., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2142 · Cited by 410
Vesselle, H. J., Schmidt, R. A., Pugsley, J. M., Li, M., Kohlmyer, S. G., Vallires, E., & Wood, D. E. (2000) · PubMed · Cited by 351
Sites of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies.
Feld, R., Rubinstein, L. V., & Weisenberger, T. H. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.12.1352 · Cited by 321
Mac Manus, M. P., Hicks, R. J., Matthews, J. P., Hogg, A., McKenzie, A. F., Wirth, A., Ware, R. E., & Ball, D. L. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01477-8 · Cited by 297
Vanuytsel, L., Vansteenkiste, J., Stroobants, S. G., Leyn, P. R. D., Wever, W. D., Verbeken, E. K., Gatti, G. G., Huyskens, D. P., & Kutcher, G. J. (2000) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(00)00138-9 · Cited by 286
Higashi, K., Ueda, Y., Arisaka, Y., Sakuma, T., Nambu, Y., Oguchi, M., Seki, H., Taki, S., Tonami, H., & Yamamoto, I. (2002) · PubMed · Cited by 272
Allal, A. S. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1398 · Cited by 219
Ryu, J.-S., Choi, N. C., Fischman, A. J., Lynch, T. J., & Mathisen, D. J. (2002) · Lung Cancer · doi:10.1016/s0169-5002(01)00332-4 · Cited by 200
Kostakoğlu, L., & Goldsmith, S. J. (2003) · PubMed · Cited by 172
Pauwels, E. K. J., Sturm, E. J. C., Bombardieri, E., Cleton, F. J., & Stokkel, M. P. M. (2000) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/pl00008465 · Cited by 169
Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer.
Crippa, F., Agresti, R., Seregni, E. C., Greco, M., Pascali, C., Bogni, A., Chiesa, C., Sanctis, V. D., Delledonne, V., Salvadori, B., et al. (1998) · PubMed · Cited by 150
Clinical Factors and Prognosis in Non–Small Cell Lung Cancer
Martins, S. J., & Pereira, J. R. (1999) · American Journal of Clinical Oncology · doi:10.1097/00000421-199910000-00006 · Cited by 61
Positron-emission tomographic imaging of cancer: Glucose metabolism and beyond*
Mankoff, D. A., & Bellon, J. R. (2001) · Seminars in Radiation Oncology · doi:10.1053/srao.2001.18100 · Cited by 58
Cited by
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057307 · Cited by 3,777
“However, several papers have shown that in lung cancer, for example, a decline in a tumor SUV to below 4–6 after treatment separates groups of patients with longer and shorter survival reasonably well (72,127).”
BackgroundBerghmans, T., Dusart, M., Paesmans, M., Hossein-Foucher, C., Buvat, I., Castaigne, C., Scherpereel, A., Mascaux, C., Moreau, M., Roelandts, M., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31815e6d6b · Cited by 524
Kidd, E. A., Siegel, B. A., Dehdashti, F., & Grigsby, P. W. (2007) · Cancer · doi:10.1002/cncr.22974 · Cited by 288
Paesmans, M., Berghmans, T., Dusart, M., Garcia, C., Hossein-Foucher, C., Lafitte, J.-J., Mascaux, C., Meert, A.-P., Roelandts, M., Scherpereel, A., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181d0a4f5 · Cited by 262
Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer
Chung, H. H., Kim, J. W., Han, K. H., Eo, J. S., Kang, K. W., Park, N.-H., Song, Y.-S., Chung, J.-K., & Kang, S.-B. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.11.002 · Cited by 126
Metadata
- Authors
- Sasaki, R., Komaki, R., Macapinlac, H., Erasmus, J., Allen, P., Forster, K., Putnam, J. B., Herbst, R. S., Moran, C. A., Podoloff, D. A., Roth, J. A., & Cox, J. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-02-20
- Volume
- 23
- Issue
- 6
- Pages
- 1136-1143
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2151525176
- Cited by
- 277
- References
- 21
- FWCI
- 21.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.